一种化-叶酸组合改善了SCA2-58Q小鼠的认知情感下降
Ksenia S Marinina1, Ilya B Bezprozvanny2,3, Polina A Egorova4
1Laboratory of Molecular Neurodegeneration, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia.
Scientific reports
|August 3, 2023
概括
这项研究研究了用于治疗2型脊髓脑动症 (SCA2) 的组合疗法. 佐和叶酸改善了小鼠的运动和认知功能,但没有影响小脑Purkinje细胞的发射.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型脊髓脑动症 (SCA2) 是一种由ATXN2基因CAG重复扩张引起的神经退行性疾病.
- SCA2主要影响小脑Purkinje细胞 (PCs),导致运动衰退和潜在的非运动症状,如认知和情感缺陷.
- 之前对SCA2-58Q小鼠的研究显示了运动缺陷,空间记忆力下降和类似抑郁的行为.
研究的目的:
- 评估在SCA2-58Q小鼠中结合氧沙 (CHZ) 和叶酸 (FA) 的治疗潜力.
- 评估CHZ-FA治疗对SCA2模型中的运动,认知和情感症状的影响.
- 为了确定CHZ-FA是否影响SCA2-58Q小鼠中小脑Purkinje细胞的燃烧速度.
主要方法:
- 使用了SCA2-58Q转基因小鼠,用于脊髓小脑动症2型的模型.
- 进行了氧沙 (CHZ) 和叶酸 (FA) 的联合治疗.
- 评估了运动功能,空间记忆,情绪相关的行为,以及普尔金涅细胞发射率.
主要成果:
- 在SCA2-58Q小鼠中,CHZ-FA组合显著改善了运动和认知缺陷.
- 在SCA2模型中观察到的CHZ-FA治疗改善了类似抑郁和类似焦虑的行为.
- 重要的是,治疗效益在不改变小脑Purkinje细胞的燃烧速度的情况下得到.
结论:
- 用CHZ和FA进行组合疗法在SCA2.2中治疗运动和非运动症状方面表现有前途.
- 这种方法为SCA2提供了潜在的治疗策略,可以保持正常的普金尼细胞电生理学.
- 对CHZ-FA组合治疗的进一步研究可能会使SCA2和类似的多重谷氨酸乱症患者受益.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.0K
03:19Author Spotlight: Studying the Impact of Maternal Dietary Deficiencies on Long-Term Offspring Health Outcomes
Published on: June 28, 2024
457
相关概念视频
01:22Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
155
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
155
01:26Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521